文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

立体定向放射治疗猪室间隔的安全性与可行性初步研究

[Safety and feasibility of stereotactic radiation therapy on porcine ventricular septum: a preliminary study].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2022-01-01

该研究用5头雄性小型猪探索SBRT照射室间隔的安全性与可行性,2头接受25 Gy、3头接受40 Gy,均存活至6个月。照射后cTnT和NT-proBNP一过性升高,1周回落;6个月时靶区出现坏死和纤维化,非靶区无损伤,左心室射血分数和舒张末期内径无变化。

要点

  • SBRT照射猪室间隔安全可行,动物均存活至6个月。
  • 照射后cTnT和NT-proBNP一过性升高,1周内回落。
  • 6个月时靶区出现坏死和纤维化,非靶区无损伤。

核心结论

  • SBRT照射猪心脏室间隔安全、可行,可为临床SBRT治疗肥厚型梗阻性心肌病提供初步实验证据。

研究设计与样本

  • 研究纳入5头雄性小型猪(39~49 kg,6月龄),2头接受25 Gy照射,3头接受40 Gy照射。
  • CT三维影像重建指导勾画靶区,采用SBRT进行靶区照射。
  • 照射前、后行血生化、彩色超声心动图、心电图检查,照射后6个月处死动物行心肌病理检查。

主要发现

  • 5头猪均顺利完成靶区照射并存活至照射后6个月。
  • 照射后1天cTnT较基线明显升高,1周降低但仍高于基线(P<0.05);NT-proBNP照射后1天明显升高(P<0.05),1周基本恢复至基线。
  • 40 Gy剂量组照射前、照射后1天和1周NT-proBNP分别为(249±78)、(594±37)和(234±46)pg/ml,cTnT分别为(14±7)、(240±40)和(46±34)pg/ml。
  • 25 Gy剂量组照射前、照射后1天和1周NT-proBNP分别为(184±20)、(451±49)和(209±36)pg/ml,cTnT分别为(9±1)、(176±29)和(89±27)pg/ml。
  • 40 Gy剂量组NT-proBNP和cTnT有高于25 Gy剂量组的趋势,但差异无统计学意义(P>0.05)。

关键数值与推荐

  • 照射前、照射后1周及6个月左心室射血分数无明显变化(P>0.05),左心室舒张末期内径无明显扩大(P>0.05)。
  • 照射后6个月室间隔厚度较照射前有减小趋势但差异无统计学意义[(9.54±0.24)mm比(9.82±8.00)mm,P>0.05]。
  • 两组合并分析,照射靶区坏死区域面积占整个室间隔面积的(26±9)%,高于非照射靶区(0)(P<0.05)。
  • Masson染色示靶区纤维化面积分数高于非靶区[(12.6±5.3)%比(2.5±0.8)%,P<0.05]。

临床怎么用

  • SBRT可用于猪室间隔照射且未观察到靶区外心肌损伤,支持进一步开展临床转化研究。
  • 照射后需监测cTnT和NT-proBNP以评估心肌损伤程度。
  • 随访中左心室射血分数、舒张末期内径及瓣膜功能未见异常,提示短期安全性良好。

局限性

  • 样本量小(共5头猪),且为动物实验,结论外推至人类需谨慎。
  • 40 Gy与25 Gy剂量组间心肌损伤标志物差异无统计学意义,剂量效应关系尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the safety and feasibility of stereotactic radiation therapy (SBRT) strategy for irradiating porcine ventricular septum, see if can provide a preliminary experimental evidence for clinical SBRT in patients with hypertrophic obstructive cardiomyopathy (HOCM). Methods: Five male pigs (39-49 kg, 6 months old) were used in this study. Pigs were irradiated at doses of 25 Gy (n=2) or 40 Gy (n=3). Delineation of the target volume was achieved under the guidance of 3-dimensional CT image reconstruction, and SBRT was then performed on defined target volume of porcine ventricular septum. Blood biomarkers, electrocardiogram and echocardiography parameters were monitored before and after SBRT. Pathological examination (HE staining, Masson staining) was performed on the target and non-target myocardium at 6 months post SBRT. Results: SBRT was successful and all animals survived to the designed study endpoint (6 months) after SBRT. Serum cardiac troponin T (cTnT) level was significantly higher than the baseline level at 1 day post SBRT, and reduced at 1 week after SBRT, but was still higher than the baseline level(P<0.05). Serum N-terminal pro-B type natriuretic peptide (NT-proBNP) was also significantly increased at 1 day post SBRT (P<0.05) and returned to baseline level at 1 week post SBRT. The serum NT-proBNP level was (249±78), (594±37) and (234±46) pg/ml, respectively, and the cTnT was (14±7), (240±40) and (46±34) pg/ml, respectively at baseline, 1 day and 1 week after SBRT in the 40 Gy dose group. The serum NT-proBNP level was (184±20), (451±49) and (209±36) pg/ml, respectively, the cTnT values were (9±1), (176±29) and (89±27) pg/ml, respectively at baseline, 1 day and 1 week after SBRT in the 25 Gy dose group. Both NT-proBNP and cTnT values tended to be higher post SBRT in the 40 Gy dose group as compared with the 25 Gy dose group, but the difference was not statistically significant (P>0.05). The left ventricular ejection fraction and the left ventricular end-diastolic diameter remained unchanged before and after SBRT (P>0.05). The interventricular septum thickness showed a decreasing trend at 6 months after SBRT, but the difference was not statistically significant ((9.54±0.24) mm vs. (9.82±8.00) mm, P>0.05). The flow velocity of the left ventricular outflow tract, and the valve function and morphology were not affected by SBRT. At 6 months after SBRT, HE staining revealed necrosis in the irradiated target area of the myocardium in the 40 Gy dose group and the 25 Gy dose group, and the degree of necrosis in the irradiated interventricular septum was more obvious in the 40 Gy dose group as compared with the 25 Gy group. The combined histological analysis of the two groups showed that the necrotic area of the irradiated target area accounted for (26±9)% of the entire interventricular septum area, which was higher than that of the non-irradiated area (0) (P<0.05). There was no damage or necrosis of myocardial tissue outside the target irradiation area in both groups. The results of Masson staining showed that the percentage area of myocardial fibrosis was significantly higher in the irradiated target area than non-irradiated area ((12.6±5.3)% vs. (2.5±0.8)%, P<0.05). Conclusion: SBRT is safe and feasible for irradiating porcine ventricular septum. 目的: 探讨立体定向放射治疗(SBRT)照射猪室间隔的安全性与可行性。 方法: 小型猪,雄性,39~49 kg,6月龄,5头,其中2头用于25 Gy照射(25 Gy剂量组),3头用于40 Gy照射(40 Gy剂量组)。CT三维影像重建指导勾画靶区,采用SBRT进行靶区照射。实验猪照射前、后行血生化、彩色超声心动图、心电图检查。照射后6个月后处死动物,取出心脏制作心肌病理切片,观察靶区及非靶区心肌的形态学(HE染色)及纤维化情况(Masson染色)。 结果: 5头猪均顺利完成靶区照射并存活至照射后6个月。照射后1 d,猪血清心肌肌钙蛋白T(cTnT)较基线明显升高,照射后1周又明显降低,但仍高于基线水平(P均<0.05);照射后1 d,猪血清N末端B型利钠肽原(NT-proBNP)亦较基线明显升高(P<0.05),照射后1周则基本恢复至基线水平。照射前、照射后1 d和1周,40 Gy剂量组猪血清NT-proBNP分别为(249±78)、(594±37)和(234±46)pg/ml,cTnT分别为(14±7)、(240±40)和(46± 34)pg/ml;25 Gy剂量组猪血清NT-proBNP分别为(184±20)、(451±49)和(209±36)pg/ml,cTnT分别为(9±1)、(176±29)和(89±27)pg/ml,40 Gy剂量组有高于25 Gy剂量组的趋势,但差异均无统计学意义(P均>0.05)。照射前、照射后1周及6个月,猪的左心室射血分数无明显变化(P>0.05),左心室舒张末期内径无明显扩大(P>0.05)。照射后6个月猪的室间隔厚度较照射前有减小趋势,但差异无统计学意义[(9.54±0.24)mm比(9.82±8.00)mm,P>0.05]。同时,随访过程中左心室流出道流速未见明显变化,各瓣膜活动良好,未见明显反流,也未见明显的室壁运动障碍、心包积液等。照射前,照射后即刻、1周和6个月心电图未见明显异常。照射后6个月HE染色发现40 Gy剂量组和25 Gy剂量组猪的放射治疗照射靶区心肌均出现坏死,40 Gy剂量组室间隔组织坏死更为明显。两组合并分析发现,照射靶区坏死区域面积占整个室间隔面积的(26±9)%,高于非照射靶区(0)(P<0.05)。两组靶区外心肌组织均未出现损伤和坏死。Masson染色结果示靶区纤维化面积分数高于非靶区[(12.6±5.3)%比(2.5±0.8)%,P<0.05]。 结论: SBRT照射猪心脏室间隔安全、可行。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu ZW, Li XP, Gao YW, et al. [Safety and feasibility of stereotactic radiation therapy on porcine ventricular septum: a preliminary study]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 36096709. doi:10.3760/cma.j.cn112148-20220218-00119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。